Oruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Oruka Therapeutics (NASDAQ:ORKA) to a strong-buy rating in a research report released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.03) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.46) EPS and FY2026 earnings at ($1.92) EPS.

ORKA has been the subject of a number of other research reports. Lifesci Capital began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an outperform rating and a $41.00 target price for the company. Wedbush began coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an outperform rating and a $40.00 target price for the company. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Friday, September 13th. They issued a buy rating and a $40.00 target price for the company. TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued a buy rating for the company. Finally, Leerink Partners assumed coverage on Oruka Therapeutics in a research report on Tuesday. They issued an outperform rating and a $44.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Oruka Therapeutics has a consensus rating of Buy and an average price target of $41.25.

Oruka Therapeutics Trading Up 0.7 %

Shares of NASDAQ ORKA opened at $25.00 on Tuesday. Oruka Therapeutics has a 12 month low of $18.72 and a 12 month high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.